WaferGen Biosystems, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: December 1, 2016
Pages: 50
Price:
US$ 499.00
WaferGen Biosystems, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: W6F548EC7B5BEN
Leaflet:

Download PDF Leaflet

WaferGen Biosystems, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
WaferGen Biosystems, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between WaferGen Biosystems, Inc. and its competitors. This provides our Clients with a clear understanding of WaferGen Biosystems, Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about WaferGen Biosystems, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for WaferGen Biosystems, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The WaferGen Biosystems, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes WaferGen Biosystems, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of WaferGen Biosystems, Inc. business.

About WaferGen Biosystems, Inc.

WaferGen Bio-systems, Inc. develops instruments and other commercial products to serve the genetic analysis segment of the life sciences industry.

The company produces and sells its SmartSlide Micro-incubation System (SmartSlide System), and it is developing a gene expression and genotyping product, the SmartChip Real Time PCR System (SmartChip System).

Products

SmartSlide Micro-Incubation System

The company offers SmartSlide System, a family of integrated fluidics exchange micro-incubation products that work with inverted microscopes. This technology provides a controlled environment and physiological conditions for cell biology and stem cell researchers to conduct complex time lapse imaging studies to characterize, differentiate and proliferate cells, as well as grow stem, primary and other difficult to cultivate cells.

The main element of its SmartSlide System is the compact, sterile and disposable SmartSlide-6 Micro-Incubator, which is a multi-well plate designed to maintain cells at specific physiological conditions for prolonged cell or tissue imaging. The SmartSlide-6 Micro-Incubator allows for programmable fluidics exchanging, enabling the delivery of up to six nutrient media and gas into each of its six individual wells in both intermittent and continuous perfusion modes. The SmartSlide-6 Micro-incubator is connected to the SmartSlide controller unit. Biological tissue/cells are grown directly on the SmartSlide Micro-Incubators, and the controller unit provides the right temperature, gas and/or nutrient conditions to the SmartSlide Micro-Incubator. This system eliminates the need for shuttling plates back and forth between the microscope stage and lab incubator. With the constant change of media, cells can be kept alive on the SmartSlide System for more than a month.

WaferGen has developed a family of SmartSlide System products built upon the SmartSlide-6 Micro-Incubator that offer cell biology and stem cell researchers varying levels of control over specific environmental conditions such as nutrient flow, temperature, humidity, and gas.

The company’s SmartSlide Systems have been sold to several research institutions including Abbott Labs, NASA, Harvard University, the Mayo Clinic, Memorial Sloan-Kettering, UCLA, the University of Southern California, VA Medical Centers, the University of California at Davis, the University of North Texas, Eisai Research, and the University of Georgia.

SmartChip System

The company’s SmartChip System would be provided with picoliter (one-trillionth of a liter) dispensing of oligoneucleotide reagents and nanoliter (one-billionth of a liter) dispensing of samples into a 5,000 to 30,000 well chip that would allow for high throughput real-time PCR amplification of the entire human genome in triplicate. The company’s SmartChip System chips are designed with evaporation control measures that allow for the use of nanoliter volumes, fast thermal cycling and temperature control.

In March 2010, WaferGen Biosystems, Inc. announced that Ghent University (UGent) in Belgium has signed a research collaboration and is an early-access customer for the WaferGen SmartChipT Real-Time PCR System.

Significant Events

On December 16, 2010, WaferGen Biosystems, Inc. and Integrated BioBank of Luxembourg (IBBL) announced an agreement to establish a strategic relationship that would expand the use of the WaferGen SmartChip Real-Time PCR system throughout Europe and advance personalized medicine.

Competition

SmartSlide Systems: The company’s main competitors are Solent, Bioptechs (a U.S. company), Oko Labs (an Italian company), and Tokai Hit (Japanese company). Bioptechs, Oko Labs and Tokai Hit all market and sell imaging enabling systems that compete with its SmartSlide50 System.

SmartChip Systems: The company’s competitors in the markets in which WaferGen competes are Applied Biosystems (ABI, which is a division of Applera Corporation), Affymetrix, Inc. (Affymetrix) and Illumina, Inc. (Illumina). Other companies serving the genetic analysis market include Agilent Technologies, Inc., GE Healthcare (a business segment of General Electric Company), Bio-Rad Laboratories, Inc., Stratagene Corporation, Eppendorf AG, Beckman Coulter, Inc. and F. Hoffmann-La Roche & Co. The company also competes with BioTrove and Fluidigm.

History

WaferGen Bio-systems, Inc. was founded in 2002.


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. WAFERGEN BIOSYSTEMS, INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. WAFERGEN BIOSYSTEMS, INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. WAFERGEN BIOSYSTEMS, INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. WAFERGEN BIOSYSTEMS, INC. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. WAFERGEN BIOSYSTEMS, INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. WaferGen Biosystems, Inc. Direct Competitors
5.2. Comparison of WaferGen Biosystems, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of WaferGen Biosystems, Inc. and Direct Competitors Stock Charts
5.4. WaferGen Biosystems, Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. WaferGen Biosystems, Inc. Industry Position Analysis

6. WAFERGEN BIOSYSTEMS, INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. WAFERGEN BIOSYSTEMS, INC. EXPERTS REVIEW1

7.1. Experts Opinion
7.2. Experts Estimates

8. WAFERGEN BIOSYSTEMS, INC. ENHANCED SWOT ANALYSIS2

9. UNITED STATES PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. WAFERGEN BIOSYSTEMS, INC. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. WAFERGEN BIOSYSTEMS, INC. PORTER FIVE FORCES ANALYSIS2

12. WAFERGEN BIOSYSTEMS, INC. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF TABLES

WaferGen Biosystems, Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
WaferGen Biosystems, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
WaferGen Biosystems, Inc. Major Shareholders
WaferGen Biosystems, Inc. History
WaferGen Biosystems, Inc. Products
Revenues by Segment
Revenues by Region
WaferGen Biosystems, Inc. Offices and Representations
WaferGen Biosystems, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
WaferGen Biosystems, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
WaferGen Biosystems, Inc. Capital Market Snapshot
WaferGen Biosystems, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
WaferGen Biosystems, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
WaferGen Biosystems, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

LIST OF FIGURES

WaferGen Biosystems, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
WaferGen Biosystems, Inc. 1-year Stock Charts
WaferGen Biosystems, Inc. 5-year Stock Charts
WaferGen Biosystems, Inc. vs. Main Indexes 1-year Stock Chart
WaferGen Biosystems, Inc. vs. Direct Competitors 1-year Stock Charts
WaferGen Biosystems, Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top


Ask Your Question

WaferGen Biosystems, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: